The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.
|New quinolone antibacterial eye drops TN-3262a licensed out to South Korean firm Dong-A|
|February 23, 2004|
On February 19, 2004, Toyama Chemical Co., Ltd. (President: Katsuhiko Nakano) executed a licensing agreement with South Korean firm Dong-A Pharmaceutical Co., Ltd. for the new quinolone antibacterial eye drops TN-3262a (generic name: tosufloxacin tosilate), which are currently under joint development in Japan by Toyama Chemical and Nidek Co., Ltd.
Overview of the agreement
Toyama Chemical will grant Dong-A Pharmaceutical exclusive rights to develop and sell TN-3262a in South Korea.
TN-3262a in Japan
Tosufloxacin tosilate was originated by Toyama Chemical and launched in 1990 as the oral new quinolone synthetic antibacterial Ozex Tablets. The compound is currently under development for use as eye drops (code name: TN-3262a). Based on licensing and joint development agreements concluded in 1998 between Toyama Chemical and Nidek, clinical trial on TN-3262a has been completed and preparations to filing are underway in Q2 2004. In addition, Otsuka Pharmaceutical, which already has a track record in ophthalmology sales, was granted Japanese sell rights in March 2003, in a move aimed at accelerating market penetration. Nidek had previously been granted Japanese sell rights, so both companies will market the drug in Japan.
Characteristics of TN-3262a